Merck KGaA
Avelumab (anti-PD-L1 inhibitor)
Biodrugs/ Drugs
Cancer
Javelin clinical program - avelumab in: solid tumors, renal cell carcinoma, urothelial carcinoma, merkel cell carcinoma, gastric, Head & Neck, lung, ovarian, gastroesophagic junction)
4Registration in Spain,
3Phase III in Spain,
2Phase II in Spain,
1Phase I in Spain